The Company expects REZENOPY™ to become commercially available for purchase in August. The Company is working with its wholesale distribution partners in preparation for nationwide commercial availability. The initial shipments represent an important step in Scienture's commercial strategy as it expands its portfolio of differentiated specialty pharmaceutical products.

REZENOPY™ is the highest-dose FDA-approved naloxone hydrochloride nasal spray available in the United States, delivering 10 mg of naloxone hydrochloride in a single-use nasal spray device for the emergency treatment of known or suspected opioid overdose. Built on the proven naloxone molecule and a familiar nasal spray delivery platform, REZENOPY™ is designed to provide an important treatment option for overdoses involving highly potent synthetic opioids.

According to IQVIA data (MAT April 2026), the U.S. naloxone market generated approximately $144 million in annual sales across 9.8 million units, highlighting a substantial commercial opportunity for REZENOPY™. In addition, the Company recently expanded payer access with potential coverage reaching more than 100 million covered lives, further strengthening its commercial positioning ahead of product availability.